HIV-1gp120: A Novel Viral B Cell Superantigen

References

• Goodglick L., Braun J. Revenge of the microbes. Superantigens of the T and B cell lineage. Am. J. Path. 1994; 144: 323–636
   Google Scholar
• Zouali M. B-cell superantigens: Implications for selection of the human antibody repertoire. Immunol. Today 1995; 16: 399–405
   PubMedGoogle Scholar
• Berberian L., Goodglick L., Kipps T., Braun J. Immunoglobulin VH3 gene products: Natural ligands of HIV gp120. Science 1993; 261: 1588–1591
   PubMed Web of Science ®Google Scholar
• Spear G. T., Sullivan B. L., Landay A. L., Lint T. F. Human immunodeficiency virus (HIV)-infected cells and free virus directly activate the classical complement pathway in rabbit, mouse and guinea-pig sera; activation results in virus neutralization by virolysis. Immunology 1991; 73: 377–382
   PubMed Web of Science ®Google Scholar
• Banda N. K., Bernier J., Kurahara D. K., Kurrle R., Haigwood N., Sekaly R.-P., Finel T. H. Crosslinking CD4 by human immunodeficiency virus gp120 primes T-cells for activation-induced apoptosis. J. Exp. Med. 1992; 176: 1099–1106
   PubMed Web of Science ®Google Scholar
• Finkel T. H., Banda N. K. Indirect mechanisms of HIV pathogenesis: How does HIV kill T cells. Curr. Op. in Immunol. 1994; 6: 605–615
   PubMed Web of Science ®Google Scholar
• Parker S. J., Sadlon T. A., Gordon D. L. Enhancement of NK Cell-mediated antibody-dependent lysis of recombinant gp120-coated CD4 cells by complement. J. Infect. Dis. 1995; 171: 186–189
   PubMed Web of Science ®Google Scholar
• Meyaard L., Schuitemaker H., Miedema F. T-cell dysfunction in HIV infection: Anergy due to defective antigen-presenting cell function. Immunol. Today 1993; 14: 161–164
   PubMedGoogle Scholar
• Shirai A., Cosentino M., Leitman-Klinman S. F., Klinman D. Human immunodeficiency virus infection induces both polyclonal and virus-specific B cell activation. J. Clin. Invest. 1992; 89: 561–566
   Google Scholar
• Schnittman S., Lane H., Higgins S., Folks T. Direct polyclonal activation of human B lymphocytes by the acquired immunodeficiency syndrome virus. Science 1986; 233: 1084–1088
   PubMed Web of Science ®Google Scholar
• Pahwa S., Pahwa R., Good R. A., Gallo R. C., Saxinger C. Simulatory and inhibitory influences of the human immunodeficiency virus on normal B lymphocytes. Proc. Natl. Acad. Sci. USA 1986; 83: 9124–9128
   PubMed Web of Science ®Google Scholar
• Martinez-Maza O., Crabb E., Mitsuyasu R. T., Fahey J. L., Giorgi J. V. Infection with the human immunodeficiency virus (HIV) is associated with an in vivo increase in B lymphocyte activation and immaturity. J. Immunol. 1987; 138: 3720–3724
   PubMed Web of Science ®Google Scholar
• Muller S., Richalet P., Laurent-Crawfird A., Barakat S., Riviere Y., Porrot F., Chamaret S., Briand J.-P., Montagnier L., Hovanessian A. Autoantibodies typical of non-organ-specific autoimmune diseases in HIV-seropositive patients. AIDS 1992; 6: 933–942
   PubMed Web of Science ®Google Scholar
• Berberian L., Shukla J., Jefferis R., Braun J. Effects of HIV infection on VH3 (D12 idiotope) B cells in vivo. J. AIDS 1994; 7: 641–646
   PubMedGoogle Scholar
• Berberian L., Valles-Ayoub Y., Sun N., Martinez-Maza O., Braun J. A VH clonal deficit in human immunodeficiency virus-positive individuals reflects a B-cell maturational arrest. Blood 1991; 78: 175–179
   PubMed Web of Science ®Google Scholar
• Muller S., Wang H., Silverman G. J., Bramlet G., Haigwood N., Kohler H. B-cell abnormalities in AIDS: Stable and clonally-restricted antibody response in HIV-1 infection. Scand. J. Immunol. 1993; 38: 327–334
   PubMedGoogle Scholar
• David D., Demaison C., Bani L., Zouali M., Theze J. Selective variations in vivo of VH3 and VH1 gene family expression in peripheral B cell IgM, IgD and IgG during HIV infection. Eur. J. Immunol. 1995; 25: 1524–1528
   PubMed Web of Science ®Google Scholar
• Levy J. HIV and the Pathogenesis of AIDS. ASM Press, Washington, D.C. 1994
   Google Scholar
• Maddon P. J., Dalgleish A. G., McDougal J. S., Clapham P. R., Weiss R. A., Axel R. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 1986; 47: 333–348
   PubMed Web of Science ®Google Scholar
• Shioda C.-K., Levy J. A., Cheng-Mayer C. Small amino acid changes in the V3 hypervariable region of gp120 can affect the T cell line and macrophage tropisms of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 1992; 89: 9434–9438
   PubMed Web of Science ®Google Scholar
• Shioda C.-K., Levy J. A., Cheng-Mayer C. Macrophage and T-cell line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene. Nature 1991; 349: 167–169
   PubMed Web of Science ®Google Scholar
• Mosier D., Sieburg H. Macrophage-tropic HIV: Critical for AIDS pathogenesis. Immunol. Today 1994; 15: 332–339
   PubMedGoogle Scholar
• Schuitemaker H. Macrophage-tropic HIV-1 variants: Initiators of infection and AIDS pathogenesis. J. Leuk. Biol. 1994; 56: 218–224
   PubMedGoogle Scholar
• Soto-Ramirez L. E., Renjifo B., McLane M. F., Marlink R., O'Hara C., Sutthent R., Wasi C., Vithayasai P., Vithayasai V., Apichartpiyakul C., Auewarakul P., Cruz V. C., Chui D.-S. HIV-1 Langerhans' cell tropism associated with heterosexual transmission of HIV. Science 1996; 271: 1291–1293
   PubMed Web of Science ®Google Scholar
• Townsley-Fuchs J. T., Kam L., Fairhurst R., Ganges S. J., Goodglick L., Giorgi J. V., Sidell N., Detels R., Braun J. HIV-1 gp120 superantigen-binding serum antibodies. A host factor in homosexual HIV-1 transmission. J. Clin. Invest. 1996; 98: 1794–1801
   PubMed Web of Science ®Google Scholar
• Herman A., Kappler J. W., Marrack P., Pullen A. M. Superantigens: Mechanism of T-cells stimulation and role in immune responses. Annu. Rev. Immunol. 1991; 9: 745–772
   PubMed Web of Science ®Google Scholar
• Hillson J. L., Karr N. S., Oppliger I. R., Mannik M., Sasso E. H. The structural basis of germline-encoded VH3 immunoglobulin binding to staphylococcal protein A. J. Exp. Med. 1993; 178: 331–336
   PubMed Web of Science ®Google Scholar
• Randen I., Potter K. N., Li Y., Thompson K. M., Pascual V., Forre O., Natvig J. B., Capra J. D. Complementarity-determining region 2 is implicated in the binding of staphylococcal protein A to human immunoglobulin VHIII variable regions. Eur. J. Immunol. 1993; 23: 2682–2686
   PubMedGoogle Scholar
• Sasso E. H., Silverman G. J., Mannik M. Human IgA and IgG F(ab)2 that bind to staphylococcal protein A belong to the VHIII subgroup. J. Immunol. 1991; 147: 1877–1883
   PubMed Web of Science ®Google Scholar
• Sassa E. H., Silverman G. J., Mannik M. Human IgM molecules that bind staphylococcal protein A contain VHIII chains. J. Immunol. 1989; 142: 2778–2783
   PubMedGoogle Scholar
• Goodglick L., Zevit N., Neshat M. S., Braun J. Mapping the Ig superantigen-binding site of HIV-1 gp120. J. Immunol. 1995; 155: 5151–5159
   PubMed Web of Science ®Google Scholar
• Margolin D. H., Reimann K. A., Sodroski J., Montefiori D. C., Tenner-Racz K., Racz P., Letvin M. L. Immunoglobulin VH usage during primary infection of rhesus monkeys with simian-human immunodeficiency virus, submitted for publication
   Google Scholar
• Los Alamos National Laboratories, Human Retroviruses and AIDS. A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences December, 1995
   Google Scholar
• Jiang S., Lin K., Neurath A. R. Enhancement of human immunodeficiency virus type 1 infection by antisera to peptides from the envelope glycoproteins gp120/gp41. J. Exp. Med. 1991; 174: 1557–1563
   PubMedGoogle Scholar
• Takeda A., Robinson J. E., Ho D. D., Debouck C., Haigwood N. L., Ennis F. A. Distinction of human immunodeficiency virus type 1 neutralization and infection enhancement by human monoclonal antibodies to glycoprotein 120. J. Clin. Invest. 1992; 89: 1992–1957
   Google Scholar
• Montefiori D. C., Pantaleo G., Fink L. M., Zhou J. T., Zhou J. Y., Bilska M., Miralles G. D., Fauci A. S. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. J. Infect. Dis. 1996; 173: 60–67
   PubMed Web of Science ®Google Scholar
• Spear G. T., Takefman D. M., Sharpe S., Ghassemi M., Zolla-Pazner S. Antibodies to the HIV-1 V3 loop in serum from infected persons contribute a major proportion of immune effector functions including complement activation, antibody binding, and neutralization. Virology 1994; 204: 609–615
   PubMed Web of Science ®Google Scholar
• Zolla-Pazner S., Gorny M. K. Passive immunization for the prevention and treatment of HIV infection. AIDS 1992; 6: 1235–1247
   PubMed Web of Science ®Google Scholar
• Forthal D. N., Landucci G., Gorny M. K., Zoll-Pazner S., Robinson W. E. Functional activities of 20 human immunodeficiency virus type 1 (HIV-1)-specific human monoclonal antibodies. AIDS Res. and Hum. Retrovir. 1995; 11: 1095–1099
   PubMedGoogle Scholar
• Sidell N., Connor M. J., Chang B., Lowe N. J., Borok M. Effects of 13-cis retinoic acid therapy on human antibody responses to defined proteins antigens. J. Invest. Derm. 1990; 95: 597–602
   PubMed Web of Science ®Google Scholar
• Kaslow R. A., Ostrow D. G., Detels R., Phair J. P., Polk B. F., Rinaldo C. R. The Multicenter AIDS Cohort Study: Rationale, organization, and selected characteristics of participants. Am. J. Epi. 1987; 126: 310–318
   PubMed Web of Science ®Google Scholar
• Law C. L., Qassim M., Cunningham A. L., Mulhall B., Grierson J. M. Nonspecific proctitis: Association with human immunodeficiency virus infection in homosexual men. J. Infect. Dis. 1992; 165: 150–154
   PubMedGoogle Scholar
• Torian L. V., Weisfuse I. B., Makki H. A., Benson D. A., DiCamillo L. M., Toribio F. E. Increasing HIV-1 seroprevalence associated with genital ulcer disease, New York City, 1990–1992. Aids 1995; 9: 177–181
   PubMedGoogle Scholar
• Koziol D. E., Saah A. J., Odaka N., Munoz A. A comparison of risk factors for human immunodeficiency virus and hepatitis B virus infections in homosexual men. Ann. of Epi. 1993; 3: 434–441
   PubMedGoogle Scholar
• Spear G. T., Takefman D. M., Sullivan B. L., Landay A. L., Zolla-Pazner S. Complement activation by human monoclonal antibodies to human immunodeficiency virus. J. Virol. 1993; 67: 53–59
   PubMed Web of Science ®Google Scholar
• Paul W. Fundamental Immunology. Raven Press, New York, N.Y. 1993
   Google Scholar
• Schlesinger L. S., Hororwita M. A. A role for natural antibody in the pathogenesis of leprosy: Antibody in nonimmune serum mediates C3 fixation to the Mycobacterium leprae surface and hence phagocytosis by human mononuclear phagocytes. Infect, and Immun. 1994; 62: 280–289
   PubMedGoogle Scholar
• Schlesinger L. S., Horowitz M. A. Phagocytosis of leprosy bacilli is mediated by complement receptors CR1 and CR3-on human monocytes and complement componene C3 in serum. J. Clin. Invest. 1990; 85: 1304–1314
   PubMed Web of Science ®Google Scholar
• Susal C., Kirschfink M., Kropelin M., Daniel V., Opelz G. Complement antivation by recombinant HIV-1 glycoprotein gp120. J. Immunol. 1994; 152: 6028
   PubMedGoogle Scholar
• Mouhoub A., Thieblemont N., Delibrias C., Fischer E., Kazatchkine M. D. Enhancing role of complement in HIV infection. Clin, and Exp. Immunol. 1994; 9–11, Suppl. 2
   PubMedGoogle Scholar
• Boyer V., Desgranges C., Trabaud M.-A., Fischer E., Kazatchkine M. D. Complement mediates human immunodeficiency virus type 1 infection of a human T cell line in a CD4- and antibody-independent fashion. J. Exp. Med. 1991; 173: 1151–1158
   PubMed Web of Science ®Google Scholar
• Ebenbichler C. F., Thielens N. M., Vornhagen R., Marschang P., Arlaud G. J., Dierich M. P. Human immunodeficiency virus type 1 activates the classical pathway of complement by direct CI binding through specific sites in the transmembrane glycoprotein gp41. J. Exp. Med. 1991; 174: 1417–1424
   PubMedGoogle Scholar
• Stoiber H., Ebenbichler C., Schneier R., Janatova J., Dierich M. P. Interaction of several complement proteins with gp120 and gp41, the two envelope glycoproteins of HIV-1. AIDS 1995; 9: 19–26
   PubMed Web of Science ®Google Scholar
• Montefiori DC, Stewart K., Ahearn J. M., Zhou J., Zhou J. Complement-mediated binding of naturally glycosylated and glycosylation-modified human immunodeficiency virus type 1 human CR2 (CD21). J. Virol. 1993; 67: 2699–2706
   PubMedGoogle Scholar
• Saarloos M. N., Lint T. F., Spear G. T. Efficacy of HIV-specific and antibody-independent mechanisms for complement activation by HIV-infected cells. Clin. Exp. Immunol. 1995; 99: 189–195
   PubMedGoogle Scholar
• Kirkham P. M., Mortari F., Newton J. A., Schroeder H. W. Immunoglobulin VH clan and family identity predicts variable domain structure and may influence antigen binding. EMBO. J. 1992; 11: 603–609
   PubMed Web of Science ®Google Scholar
• Schroeder H. W., Mortari F., Shiokawa S., Kirkham P. M., Elgavish R. A., Bertrand F. E. Developmental regulation of the human antibody repertoire. Annals N. Y. Acad. Sci. 1995; 764: 242–260
   PubMed Web of Science ®Google Scholar
• Silverman G. J. Unconventional B-cell antigens and human immune repertoires. Annals N. Y. Acad. Sci. 1995; 764: 342–355
   PubMedGoogle Scholar
• Silverman G. J., Roben P., Bouvet J. P., Sasano M. Superantigen properties of a human sialoprotein involved in gut-associated jmmunity. J. Clin. Invest. 1995; 96: 417–426
   PubMed Web of Science ®Google Scholar